US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SIMPLIFY MANAGED FUTURES STRATEGY ETF

28.16

+0.03000.11%

Post-market: 28.160.00000.00%16:58 EDT

Volume:195.63K

Turnover:5.50M

Market Cap:- -

PE:- -

High:28.24

Open:28.19

Low:28.00

Close:28.13

Loading ...

Overview Company News Filings

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

Press Release: Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

Press Release: Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

Financial Services Firms Deepen Client Engagement with ON24-powered Digital Experiences

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

ACCESS Newswire

Press Release: Gentex Announces Closing of VOXX International Acquisition

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

ACCESS Newswire

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

Press Release: CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Why Prime Medicine Stock Was Climbing Higher This Week

Press Release: Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

ProQR Announces Year End 2024 Operating and Financial Results

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Tired of subway delays? The MTA wants to fix that by strapping Google smartphones to New York trains

Press Release: Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CTA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","market":"US","secType":"STK","nameCN":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","latestPrice":28.16,"timestamp":1749672000000,"preClose":28.13,"halted":0,"volume":195627,"hourTrading":{"tag":"盘后","latestPrice":28.16,"preClose":28.16,"latestTime":"16:58 EDT","volume":29,"amount":819.04,"timestamp":1749675482849},"delay":0,"floatShares":38775001,"shares":0,"eps":0,"marketStatus":"Closed","change":0.03,"latestTime":"06-11 16:00:00 EDT","open":28.19,"high":28.24,"low":28,"amount":5500272.794121,"amplitude":0.008532,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749715200000},"marketStatusCode":5,"adr":0,"exchange":"AMEX","adjPreClose":28.13,"sharesOutstanding":38775001,"nav":28.08,"aum":1088746790.07,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":28.16,"preClose":28.16,"latestTime":"16:58 EDT","volume":29,"amount":819.04,"timestamp":1749675482849},"volumeRatio":0.537828,"impliedVol":0.1566,"impliedVolPercentile":0.5301},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","floatShares":38775001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.537828,"shares":0,"dividePrice":0,"high":28.24,"amplitude":0.008532,"preClose":28.13,"low":28,"week52Low":25.6601,"pbRate":"--","week52High":30.213,"institutionHeld":0,"latestPrice":28.16,"eps":0,"divideRate":0,"volume":195627,"delay":0,"ttmEps":0,"open":28.19,"prevYearClose":27.89,"prevWeekClose":27.92,"prevMonthClose":27.11,"prevQuarterClose":29.6,"fiveDayClose":27.25,"twentyDayClose":27.85,"sixtyDayClose":29.35},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540719842","title":"Why AbCellera Biologics Stock Raced Nearly 6% Higher Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2540719842","media":"Motley Fool","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540719842?lang=en_us&edition=fundamental","pubTime":"2025-06-03 06:45","pubTimestamp":1748904300,"startTime":"0","endTime":"0","summary":"The company had some encouraging regulatory news to report.It concerned a dermatitis drug the biotech is currently developing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/02/why-abcellera-biologics-stock-raced-nearly-6-highe/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["CTA","BK4535","BK4121","ABCL"],"gpt_icon":0},{"id":"2536812996","title":"Press Release: Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2536812996","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536812996?lang=en_us&edition=fundamental","pubTime":"2025-05-19 20:31","pubTimestamp":1747657860,"startTime":"0","endTime":"0","summary":"-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology --. -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --. -- Implementing cost cutting measures to significantly reduce cash needs in advance of key data inflection points --. \"The first-in-human data for PM359 announced today represent a landmark moment for the industry and for our company, demonstrating the unequivocal power of Prime Editing to change patients' lives, with a single dose of PM359 providing potentially curative benefit in a matter of weeks,\" said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. \"These data also reinforce the critical importance of ensuring Prime Medicine is positioned to withstand the challenges of the current environment, so that we can one day deliver the tremendou","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CFO","PRME","BK4022","CEO","BK4585","BK4588","TM","BK4099","03160","BK4604","BK4555","CTA","BK4232","R","BK4139"],"gpt_icon":0},{"id":"2535042243","title":"Press Release: Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535042243","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535042243?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220400,"startTime":"0","endTime":"0","summary":"Clinical Trials of Budoprutug in Primary Membranous Nephropathy , Immune Thrombocytopenia , and Systemic Lupus Erythematosus  on Track to Initiate in 2025. CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025. Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer. Strong Financial Position, with Cash Runway Expected Through 2027. \"2025 is a critical year of execution for Climb Bio and we continue to make excellent progress developing a differentiated pipeline targeting immune-mediated diseases with expansive therapeutic and commercial potential,\" said Aoife Brennan, President and CEO of Climb Bio. \"Our most advanced program, budoprutug, a potential best-in-class anti-CD19 monoclonal antibody designed to treat B-cell mediated diseases, remains on track to initiate clinical studies in ITP and SLE in the coming weeks and in pMN in the second half of 2025. We plan to provide clarity on the","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA","BK4077","BK4199","CLYM","BK4539","ITP","BK4139","SLE"],"gpt_icon":0},{"id":"2531942392","title":"Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531942392","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531942392?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:30","pubTimestamp":1745872200,"startTime":"0","endTime":"0","summary":"BURLINGTON, Mass., April 28, 2025  -- Fractyl Health, Inc.  , a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes , today announced that it will deliver an oral presentation of compelling preclinical data from its Rejuva single-administration Smart GLP-1 pancreatic gene therapy platform at the American Society of Gene and Cell Therapy  2025 Annual Meeting, taking place May 13-17, 2025, in New Orleans, Louisiana.Title: Endoscopic Ultrasound-Guided Delivery of Human Glucagon-like Peptide-1 Pancreatic Gene Therapy: Safety and Feasibility in a Porcine ModelSession: AAV Preclinical and Proof-of-Concept StudiesDate and Time: Saturday, May 17, 2025, 9:15 a.m. – 9:30 a.m. CTLocation: NOLA Theater A. Investor Contact Brian Luque, Head of Investor Relations and Corporate DevelopmentIR@fractyl.com, 951.206.1200","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fractyl-health-present-compelling-preclinical-203000689.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","BK4082","BK4590","BK4117","GLP","CTA","BK4144","GUTS","BK4107"],"gpt_icon":0},{"id":"2530402730","title":"Financial Services Firms Deepen Client Engagement with ON24-powered Digital Experiences","url":"https://stock-news.laohu8.com/highlight/detail?id=2530402730","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530402730?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"New research reveals how digital-first strategies are driving stronger relationships and propelling business outcomes. SAN FRANCISCO, April 28, 2025----ON24 , a leading intelligent engagement platform for B2B sales and marketing, today released its 2025 Financial Services Digital Engagement Benchmarks Report, highlighting how financial services and asset management firms are transforming client education through digital engagement. The findings show a surge in interactive, data-driven experiences, with firms leveraging first-party engagement from webinars, virtual events, and content hubs to foster deeper relationships, enhance awareness and drive pipeline growth.\"The finance industry isn’t just going digital – it's racing towards hyper-personalization,\" said Mark Bornstein, VP of Marketing, ON24. \"Our research shows that firms that combine scalability with personalization see stronger engagement, more meaningful client interactions and ultimately, better business outcomes. The ON24 pl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/financial-services-firms-deepen-client-120000695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONTF","CTA","BK4023"],"gpt_icon":0},{"id":"2527629431","title":"Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2527629431","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527629431?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:00","pubTimestamp":1744801200,"startTime":"0","endTime":"0","summary":"Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025. CLN-978 is also being studied in the U.S., Europe, and Australia for systemic lupus erythematosus. About CLN-978CLN-978 is a novel, differentiated and highly potent CD19xCD3 bispecific T cell engager. CLN-978 triggers redirected lysis of CD19-expressing target cellsin vitroandin vivo. CLN-978 is engineered to achieve very high affinity binding to CD19 to efficiently target B cells, including those with very low CD19 levels. Small in molecular size , CLN-978 contains two single-chain variable fragments, one b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cullinan-therapeutics-receives-approval-european-110000424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MDCO","BK4139","ACR","CTA","BK4110","CGEM"],"gpt_icon":0},{"id":"2526923550","title":"CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2526923550","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526923550?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:30","pubTimestamp":1744284600,"startTime":"0","endTime":"0","summary":"Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation. Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precision immunotherapy CVGBM; Part B first data readout anticipated in H2 2025. Filed IND and CTA submissions for Phase 1 study with proprietary off-the-shelf program in squamous non-small cell lung cancer . Received FDA clearance to proceed with sqNSCLC Phase 1 study; expected tostart in H2 2025. Invoiced 10 million milestone payment following initiation of Phase 1 of the combined Phase 1/2 study of a seasonal influenza/COVID-19 combination vaccine; program fully licensed to GSK. Received positive validity decision for patent EP 3 708 668 B1 in amended form from European Patent Office  in inter partes proceedings against BioNTech SE. Cash and cash equivalents position of 481.7 million as of December 31, 2024; reaffirming expected cash runway into 2028. TBINGEN, GERMANY AND BOSTON, MA / ACCESS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/curevac-announces-financial-results-fourth-113000748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTA","BK4548","BNTX","BK4588","CVAC","SITC","BK4568","BK4535","BK4585","BK4139","BK4080","BK4551","BK4231"],"gpt_icon":0},{"id":"2524111983","title":"Press Release: Gentex Announces Closing of VOXX International Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2524111983","media":"Dow Jones","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524111983?lang=en_us&edition=fundamental","pubTime":"2025-04-01 21:00","pubTimestamp":1743512400,"startTime":"0","endTime":"0","summary":"ZEELAND, Mich., April 01, 2025  -- Gentex Corporation  announced today that it has closed on the strategic acquisition of VOXX International, a global supplier of automotive and consumer electronics as well as premium audio equipment.Gentex is a technology company and long-time supplier of electro-optical products for the global automotive, aerospace, fire protection and medical industries. The company is best known for automotive electronics, but continues to grow its capabilities in vision systems, sensing, AI development, biometrics, home automation, and other smart technologies.Under the terms of the agreement, which was recently approved by VOXX shareholders, Gentex acquired all the issued and outstanding shares of VOXX common stock not already owned by Gentex for a purchase price of $7.50 per share. The Company expects its annual revenue to increase in the range of $325 million to $375 million as a result of the acquisition.\"We want to continue the legacy of VOXX Founder John Sha","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4232","GNTX","VOXX","CTA","R","BK4078","BK4124","IE00BD6J9T35.USD"],"gpt_icon":0},{"id":"2523947806","title":"CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2523947806","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523947806?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:15","pubTimestamp":1743423300,"startTime":"0","endTime":"0","summary":"BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. , , a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the fourth quarter ended December 31, 2024, and provided an update on key highlights for 2024.Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, \"2024 was a transformative year for CASI as we strategically pivoted our company toward the development of CID-103 for organ transplant rejection and autoimmune disease. CID-103 is an anti-CD38 antibody with the potential to be a best-in-class treatment for a myriad of autoimmune diseases as well as antibody mediated rejection . We are encouraged by our clinical progress, achieving a milestone with the first Immune Thrombocytopenia  patient dosed in January 2025. Simultaneously, we are diligently working towards resolution of the FDA renal allograft ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/casi-pharmaceuticals-announces-fourth-quarter-121500480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","AMR","BK4199","CASI","BK4139","CTA","CDE","ITP","BK4017","BK4588","BK4006"],"gpt_icon":0},{"id":"2523917675","title":"Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2523917675","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523917675?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical mu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052163/36461/en/Voyager-Presents-Robust-Preclinical-Data-from-Tau-Targeting-Gene-Therapy-and-Antibody-Programs-at-AD-PD-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4192","PD","LU1169589451.USD","PET","CTA","BK4023","LU1169590202.USD"],"gpt_icon":0},{"id":"2522539191","title":"Press Release: CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539191","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539191?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"-- Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders  ongoing, with dosing completed in two of four multiple ascending dose  cohorts; safety, pharmacokinetic, and pharmacodynamic data anticipated in Q4 2025. -- Nomination of development candidate CMP-SYNGAP-01 to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025. Mr. Mandel-Brehm continued, \"We are also pleased to announce the selection of a development candidate, CMP-SYNGAP-01, for our SYNGAP1-related disorders program based on compelling data across our preclinical studies, including recent non-human primate studies. The discovery and selection of a novel regRNA-targeting antisense oligonucleotide  that increases SYNGAP1 protein levels underscores the transformative potential of our platform to identify and advance this novel class of therapeutic candidates for SYNGAP1-related disorders, a group of neurodevelopmental conditions with no approved therapies that we believe impacts app","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4588","LU1169590202.USD","BK4200","BK4585","BK4020","BK4561","LU1169589451.USD","PD","BK4099","CTA","BK4555","BK4023","TM","ASO","CAMP","03160","BK4139"],"gpt_icon":0},{"id":"2522580965","title":"Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522580965","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522580965?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:01","pubTimestamp":1742986860,"startTime":"0","endTime":"0","summary":"- Announced first in vivo clinical validation for ARCUS gene editing across two distinct programs including wholly owned PBGENE-HBV and partnered program ECUR-506 -. - Commenced Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV, the first gene editing technology studied for Hepatitis B, in fourth quarter of 2024 -. - Demonstrated PGENE-HBV was safe and well tolerated with substantial antiviral activity measured by reduction of Hepatitis B surface antigen after only one administration at lowest dose level; Subsequent doses of PBGENE-HBV to follow with data expected throughout 2025 -. \"In 2025, our steadfast focus remains on continued clinical execution as we work to deliver on the promise of our ARCUS gene editing technology through robust clinical data,\" continued Mr. Amoroso. \"The recent reported clinical experience for PBGENE-HBV focused on viral editing and elimination of replicating cccDNA and integrated HBV DNA in Hepatitis B, an extremely large patient population, adds to the com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/precision-biosciences-reports-fourth-quarter-110100032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DTIL","CTA","GHS","BK4139"],"gpt_icon":0},{"id":"2521418875","title":"Why Prime Medicine Stock Was Climbing Higher This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2521418875","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521418875?lang=en_us&edition=fundamental","pubTime":"2025-03-21 06:48","pubTimestamp":1742510880,"startTime":"0","endTime":"0","summary":"This is targeted at a genetic disorder that can affect the lungs and the liver.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/03/20/why-prime-medicine-stock-was-climbing-higher-this/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["PRME","CTA","BK4139"],"gpt_icon":0},{"id":"2520319811","title":"Press Release: Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520319811","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520319811?lang=en_us&edition=fundamental","pubTime":"2025-03-20 04:01","pubTimestamp":1742414460,"startTime":"0","endTime":"0","summary":"-- Preclinical pipeline re-prioritization to focus on four potentially. transformative programs to advance toward clinic, led by CNTY-308 in. -- New concentrated clinical focus for CNTY-101 based on unique profile with. transformational potential in autoimmune disease; data anticipated in. -- Cash runway estimate extended into fourth quarter of 2026. PHILADELPHIA, March 19, 2025  -- Century Therapeutics, Inc. , an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in autoimmune disease and cancer, today reported financial results and business highlights for the full year 2024.-- Phase 1 CALiPSO-1 trial site expansion in United States and Europe: The. first patient in our CALiPSO-1 Phase 1 trial in autoimmune diseases is. enrolled and scheduled for dosing in March 2025. Five sites in the U.S.are actively screening patients and Century has increased resourcing for. trial site activation and proficient recruitment. The company is also. expand","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4099","CAR","BK4588","BK4230","BK4539","BK4585","03160","BK4555","LENZ","TM","CNBKA","BK4139","BK4604","CTA","BK4505","IPSC"],"gpt_icon":0},{"id":"2520623482","title":"Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520623482","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520623482?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:00","pubTimestamp":1742295600,"startTime":"0","endTime":"0","summary":"-- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- -- High","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/18/3044331/0/en/Prime-Medicine-Unveils-Program-for-the-Treatment-of-Alpha-1-Antitrypsin-Deficiency-AATD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA"],"gpt_icon":0},{"id":"2520688305","title":"Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520688305","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520688305?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:05","pubTimestamp":1742241900,"startTime":"0","endTime":"0","summary":"Announced positive preliminary 12-week clinical results, building on already released 4-week results,of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplant","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/17/3044084/0/en/Sana-Biotechnology-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SANA","CTA","BK4139"],"gpt_icon":0},{"id":"2519588080","title":"ProQR Announces Year End 2024 Operating and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2519588080","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519588080?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:00","pubTimestamp":1741863600,"startTime":"0","endTime":"0","summary":"Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseasesCompany expects","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/13/3042018/33039/en/ProQR-Announces-Year-End-2024-Operating-and-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4523","LU1165135440.EUR","BK4567","CTA","BK4588","LU2092937221.SGD","LU0702159699.USD","LU0347712357.USD","LU1721428933.USD","BK4585","LU0702159343.USD","LU2413666699.HKD","BK4139","BK4505","BK4106","IE00BN0W2V16.EUR","BK4226","G","LU2413666426.HKD","A","IE00BN0W2T93.GBP","LU1543694498.USD","RNA","LU2041044095.USD","LU1166156734.SGD","BK4121","IE00BN0W2W23.USD"],"gpt_icon":0},{"id":"2518877129","title":"Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2518877129","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518877129?lang=en_us&edition=fundamental","pubTime":"2025-03-12 04:01","pubTimestamp":1741723260,"startTime":"0","endTime":"0","summary":"- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/11/3040977/36461/en/Voyager-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-and-Operating-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PET","CSF","BK4192","CTA"],"gpt_icon":0},{"id":"2518852512","title":"Tired of subway delays? The MTA wants to fix that by strapping Google smartphones to New York trains","url":"https://stock-news.laohu8.com/highlight/detail?id=2518852512","media":"CNN Business","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518852512?lang=en_us&edition=fundamental","pubTime":"2025-03-09 22:00","pubTimestamp":1741528852,"startTime":"0","endTime":"0","summary":"Rob Sarno has been with the New York City’s Metropolitan Transit Authority  for 14 years. As assistant chief track officer, he assists maintenance and emergency response — which also meant teaching artificial intelligence systems what a damaged rail sounds like last year.New York is just one major city to have implemented AI in the hopes of improving transit systems. In 2023, infrastructure consulting firm Aecom completed a pilot program for the New Jersey Transit system that used the technology to analyze customer flow and crowd management, and in 2024, the Chicago Transit Authority  uses AI to enhance security by detecting guns. Also in 2024, Beijing introduced a facial recognition system to be used in place of transit tickets and cards to reduce lines during rush hours.Google has partnered with other transportation agencies in the past. The tech giant has developed a chat box for the Chicago’s CTA, launched direct data integration for Amtrak departure and arrival times and has partn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://edition.cnn.com/2025/03/09/tech/mta-google-pixel-smartphones-new-york-subways/index.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cnn_highlight","symbols":["GOOGL","LU1551013342.USD","LU1923623000.USD","LU1496350502.SGD","GOOG","LU0787776722.HKD","LU2087625088.SGD","BK4566","LU1032955483.USD","SG9999014914.USD","LU1084165304.USD","LU1633808545.USD","LU2237443382.USD","LU0426417589.USD","LU1244550577.SGD","LU0158827948.USD","LU0788109477.HKD","MTA","LU0157215616.USD","LU1670628061.USD","LU2275660780.HKD","LU1261432733.SGD","LU1803068979.SGD","USJW.SI","IE00BN29S564.USD","LU2097344431.USD","CTA","LU0353189763.USD","LU0053666078.USD","IE00BHPRN162.USD","LU2063271972.USD","LU0127658192.USD","LU2360032135.SGD","LU0345769631.USD","LU0528227936.USD","LU2361044949.HKD","LU2491050154.USD","LU2092627202.USD","LU2552382058.USD","SGXZ31699556.SGD","LU0878866978.SGD","BK4533","LU1267930490.SGD","LU0985489474.SGD","LU0444973449.USD","LU0354030438.USD","LU0289960550.SGD","LU0310800379.SGD","BK4548","LU1548497426.USD"],"gpt_icon":1},{"id":"2516665944","title":"Press Release: Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2516665944","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516665944?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:05","pubTimestamp":1741035900,"startTime":"0","endTime":"0","summary":"Strong patient and physician demand for pivotal REMAIN-1 study highlights urgent need for post-GLP-1 withdrawal weight maintenance solutions; midpoint data analysis anticipated in Q2 2025 and full study enrollment expected in summer 2025. Company plans to submit first Clinical Trial Application  module for RJVA-001 in type 2 diabetes to regulators in H1 2025, and if CTA is authorized, expects to report preliminary data in 2026. BURLINGTON, Mass., March 03, 2025  -- Fractyl Health, Inc.  , a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes , is redefining the future of metabolic health by tackling one of obesity care's most urgent challenges -- sustaining weight loss after GLP-1 therapy. Today, the Company announced key anticipated milestones, growing patient and physician demand for its REMAIN-1 pivotal study, and fourth quarter and full year 2024 financial results, reinforcing its momentum for continued execution","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","R","CTA","GUTS","BK4022","BK4232"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":37,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTA\",params:#limit:5,,,undefined,":[{"date":"2025-03-26","symbol":"CTA","amount":0.12,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-31","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-03-31"},{"date":"2024-12-23","symbol":"CTA","amount":0.73816,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-31"},{"date":"2024-09-25","symbol":"CTA","amount":0.3,"announcedDate":"2024-09-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-25","defaultRemindTime":1727271000000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-30","payableDate":"2024-09-25","currency":"USD","dateTimestamp":1727236800000,"payDate":"2024-09-30"},{"date":"2024-06-25","symbol":"CTA","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-06-28"},{"date":"2024-03-25","symbol":"CTA","amount":0.15,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-26","defaultRemindTime":1711373400000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","recordDate":"2024-03-28","payableDate":"2024-03-26","currency":"USD","dateTimestamp":1711339200000,"payDate":"2024-03-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTA\",market:\"US\",,,undefined,":[{"executeDate":"2022-08-26","recordDate":"2022-08-29","paymentDate":"2022-08-31","value":0.15,"currency":"USD"},{"executeDate":"2022-09-27","recordDate":"2022-09-28","paymentDate":"2022-09-30","value":0.15,"currency":"USD"},{"executeDate":"2022-10-26","recordDate":"2022-10-27","paymentDate":"2022-10-31","value":0.15,"currency":"USD"},{"executeDate":"2022-11-25","recordDate":"2022-11-28","paymentDate":"2022-11-30","value":0.15,"currency":"USD"},{"executeDate":"2022-12-27","recordDate":"2022-12-28","paymentDate":"2022-12-30","value":1.11096,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTA\",market:\"US\",delay:false,,,undefined,":{}}}